Search

Your search keyword '"Tindell V"' showing total 10 results
Start Over Author "Tindell V"
10 results on '"Tindell V"'

2. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

Author

Westers, T M, Ireland, R, Kern, W, Alhan, C, Balleisen, J S, Bettelheim, P, Burbury, K, Cullen, M, Cutler, J A, Della Porta, M G, Dräger, A M, Feuillard, J, Font, P, Germing, U, Haase, D, Johansson, U, Kordasti, S, Loken, M R, Malcovati, L, te Marvelde, J G, Matarraz, S, Milne, T, Moshaver, B, Mufti, G J, Ogata, K, Orfao, A, Porwit, A, Psarra, K, Richards, S J, Subirá, D, Tindell, V, Vallespi, T, Valent, P, van der Velden, V H J, de Witte, T M, Wells, D A, Zettl, F, Béné, M C, and van de Loosdrecht, A A

Published
2012
Full Text
View/download PDF

4. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group

Author

Loosdrecht, A.A. van de, Ireland, R., Kern, W., Della Porta, M.G., Alhan, C., Balleisen, J.S., Bettelheim, P., Bowen, D.T., Burbury, K., Eidenschink, L., Cazzola, M., Chu, S.S., Cullen, M., Cutler, J.A., Drager, A.M., Feuillard, J., Fenaux, P., Font, P., Germing, U., Haase, D., Hellstrom-Lindberg, E., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Nikolova, V., Ogata, K., Oelschlaegel, U., Orfao, A., Ossenkoppele, G.J., Porwit, A., Platzbecker, U., Preijers, F.W.M.B., Psarra, K., Richards, S.J., Subira, D., Seymour, J.F., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Wells, D.A., Witte, T.J.M. de, Zettl, F., Bene, M.C., Westers, T.M., Loosdrecht, A.A. van de, Ireland, R., Kern, W., Della Porta, M.G., Alhan, C., Balleisen, J.S., Bettelheim, P., Bowen, D.T., Burbury, K., Eidenschink, L., Cazzola, M., Chu, S.S., Cullen, M., Cutler, J.A., Drager, A.M., Feuillard, J., Fenaux, P., Font, P., Germing, U., Haase, D., Hellstrom-Lindberg, E., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Nikolova, V., Ogata, K., Oelschlaegel, U., Orfao, A., Ossenkoppele, G.J., Porwit, A., Platzbecker, U., Preijers, F.W.M.B., Psarra, K., Richards, S.J., Subira, D., Seymour, J.F., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Wells, D.A., Witte, T.J.M. de, Zettl, F., Bene, M.C., and Westers, T.M.

Abstract

Item does not contain fulltext, An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.

Published
2013

5. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.

Author

Westers, T.M., Ireland, R., Kern, W., Alhan, C., Balleisen, J.S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J.A., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Ogata, K., Orfao, A., Porwit, A., Psarra, K., Richards, S.J., Subira, D., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Witte, T.J.M. de, Wells, D.A., Zettl, F., Bene, M.C., Loosdrecht, A.A. van de, Westers, T.M., Ireland, R., Kern, W., Alhan, C., Balleisen, J.S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J.A., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Ogata, K., Orfao, A., Porwit, A., Psarra, K., Richards, S.J., Subira, D., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Witte, T.J.M. de, Wells, D.A., Zettl, F., Bene, M.C., and Loosdrecht, A.A. van de

Abstract

1 juli 2012, Item does not contain fulltext, Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.

Published
2012

7. 137 Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group

Author

Westers, T.M., primary, Ireland, R., additional, Kern, W., additional, Alhan, C., additional, Balleisen, J.S., additional, Béné, M.C., additional, Bettelheim, P., additional, Burbury, K., additional, Cullen, M., additional, Cutler, J.A., additional, Porta, M.G. Della, additional, Drager, A.M., additional, Feuillard, J., additional, Font, P., additional, Germing, U., additional, Haase, D., additional, Johansson, U., additional, Kordasti, S., additional, Loken, M.R., additional, Malcovati, L., additional, te Marvelde, J.G., additional, Matarraz, S., additional, Milne, T., additional, Moshaver, B., additional, Mufti, G.J., additional, Ogata, K., additional, Orfao, A., additional, Porwit, A., additional, Psarra, K., additional, Richards, S.J., additional, Subirá, D., additional, Tindell, V., additional, Vallespi, T., additional, Valent, P., additional, van der Velden, V.H., additional, de Witte, T.M., additional, Wells, D.A., additional, Zettl, F., additional, and van de Loosdrecht, A.A., additional

Published
2011
Full Text
View/download PDF

10. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

Author

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, and Westers TM

Subjects
Humans, International Agencies, Myelodysplastic Syndromes classification, Prognosis, Reproducibility of Results, Sensitivity and Specificity, Societies, Scientific, Flow Cytometry methods, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes therapy, Outcome Assessment, Health Care methods
Abstract

An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results